Last edition
News about "AstraZeneca India "
AstraZeneca India Gets NPPA Show-Cause Notice Over Alleged Overcharging of Symbicort Turbuhaler
AstraZeneca Pharma India has received a show cause notice from the National Pharmaceutical Pricing Authority (NPPA) for allegedly overcharging on its Symbicort Turbuhaler Inhalation Powder (60 doses).
AstraZeneca India | 12/09/2025 | By Dineshwori
AstraZeneca India Secures CDSCO Approval for Durvalumab
AstraZeneca Pharma India has been granted permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion from the Central Drugs Standard Control Organisation (CDSCO).
AstraZeneca India | 27/09/2024 | By Aishwarya | 250
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy